thought call
strong perform across board though multipl
ceil becom concern
view strength share today drg index warrant given
impress result includ upsid rais guidanc
ep midpoint vs consensu though today move
attribut bearish posit given recent i/o competitor readout bristol az
certainli recogn keytruda like ga tank evidenc
upsid includ inventori build opportun sclc
tnbc nsclc penetr said concern stem rapid rise
peak keytruda forecast view larg price upsid
wouldnt expect recent competit threat like poseidon
necessarili impact keytruda domin lung posit add inher
overhang could heighten depend keytruda price dynam china
potenti deceler major eu market outsid keytruda vaccin
well unlik persist main focu oper margin
expand along revenu acceler look forward alreadi
expect uptick model bp expens step-up like
keep margin check sum like fundament pictur keytruda
margin upsid broadli appreci dont see case multipl expans
premium multipl vs peer maintain neutral rate po
what left horizon encourag today
qualiti quarter maintain bullish outlook keytruda long-term outlook across
i/o landscap neutral thesi predominantli root lack higher-impact
catalyst horizon perspect might capac drive
meaning upsid merck multipl wed highlight upcom data
tnbc import near-term updat merck
long-term growth stori although view unlik meaning move share
model chang made adjust estim follow strong
quarter rais fy revenu forecast vs prior
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
merck co global pharma compani focus
discov develop market drug
infecti diseas oncolog
indic compani global leader
vaccin diversifi anim
remain posit overal merck stori
howev neutral thesi reflect
moment rise expect
keytruda franchis expect
keytruda maintain domin posit
across i/o landscap year come see
littl room upsid current street
expect larg major higher-
impact catalyst play
made adjust merck model given report well upward
revis full year guidanc manag commentari morn
call forecast sale vs prior total revenu
vs prior bottom-lin model ep full year
vs prior ep vs prior
exhibit merck bofaml estim chang
million
million
price object po base blend averag price-to-earnings multipl
appli ep risk-adjust discount cash flow dcf dcf assum
wacc termin growth rate assum price-to-earnings multipl
base assum premium averag us major pharma group given merck
strong growth outlook acceler immuno-oncolog busi
risk po impress competitor readout result key i/o indic
nsclc rcc rapid declin across diabet franchis
expect neg outcom compani later-stag asset on-going
develop pressur headlin risk face sector includ drug
geoff meacham herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
